U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07240974) titled 'Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies' on Sept. 03.
Brief Summary: This is a single-center, single-arm, open-label, dose-escalation, early-phase 1 study to evaluate the safety, tolerability and preliminary efficacy of ZZSW-01 injection in patients with relapsed/refractory B-cell malignancies.
Study Start Date: Oct. 28
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory B-cell Malignancies
Intervention:
DRUG: ZZSW-01 injection
ZZSW-01 is an extracellular vesicle that carries functional CD19 CAR mRNA, which can be administered intravenously to generate CAR-T cells in vivo.
Recruitment ...